July 17, 2026 · European heart journal · DOI: 10.1093/eurheartj/ehag454

Clonal haematopoiesis of indeterminate potential in cardiovascular medicine: is it time for selective testing?

Listen to this summary

The authors explore whether selective testing for clonal haematopoiesis of indeterminate potential (CHIP) should be implemented in cardiovascular medicine, given its recognition as an age-related risk factor linked to somatic mutations. They argue that, with increasing knowledge about CHIP, targeted screening for high-risk individuals could enhance cardiovascular risk assessment and inform preventive strategies, despite the current lack of validated therapies. The review advocates for a biologically informed approach to assessing CHIP in clinical practice.

Ohad Oren, Peter Libby

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play